Florida Cerebrovascular Disease Biorepository and Genomics Center

Launched by MAYO CLINIC · Aug 5, 2022

Keywords

ClinConnect Summary

This clinical trial, called the Florida Cerebrovascular Disease Biorepository and Genomics Center, aims to create a valuable resource for studying various cerebrovascular diseases, which affect blood flow to the brain and can lead to conditions like strokes and vascular dementia. Researchers will collect medical history and blood samples from individuals who have experienced specific cerebrovascular issues. This information will be used in future studies to better understand these conditions and potentially improve prevention and treatment options.

To be eligible for this study, participants should be aged 65 to 74 and have been diagnosed with one of several cerebrovascular diseases, such as ischemic stroke or transient ischemic attack. It's important to note that individuals with certain infections, like HIV or tuberculosis, will not be able to participate. Those who join the trial can expect to provide some personal health information and blood samples, which will contribute to important research aimed at improving care for people with cerebrovascular diseases in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Affected subjects with diverse cerebrovascular conditions, including, but not limited to, ischemic stroke, transient ischemic attack (TIA), intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (aSAH), vascular dementia (VAD), anoxic brain injury, unruptured intracranial aneurysm (UIA), cavernous malformation, arteriovenous malformations (AVM), carotid and vertebral arterial dissections, symptomatic and asymptomatic cervical carotid artery atherosclerotic stenosis, non-aneurysmal perimesencephalic subarachnoid hemorrhage (naSAH), cerebral venous thrombosis (CVT), moyamoya disease, fibrosmuscular dysplasia (FMD), non-traumatic, angiography-negative subarachnoid hemorrhage, leukoaraiosis, arteriovenous fistula, reversible cerebral vasoconstriction syndrome (RCVS), and CADASIL.
• Exclusion Criteria:
• • All patients with the following known or suspected virulent microorganisms causing an active or latent infection will be excluded from the study:
• • Human immunodeficiency virus (HIV);
• • Any viral hepatitis;
• • West Nile virus (WNV);
• • Influenza virus;
• • Tuberculosis (TB);
• • Any bacteremia;
• • Any fungemia;
• • Any prionopathy.